Abstract
This review deals with a novel approach to produce synthetic antibiotic peptides (killer mimotopes), similar to those described for the conversion of epitopes into peptide mimotopes, allowing their use as surrogate vaccines. Synthetic peptides pertaining to the complementary determining regions (CDRs) of a recombinant antiidiotypic antibody (PaKTscFv), which mimic the wide spectrum of microbicidal activity of a killer toxin produced by the yeast Pichia anomala (PaKT), have proven to act as structural or functional mimotopes of PaKT. This activity appeared to be mediated by interaction with specific cell wall killer toxin receptors (KTRs), mainly constituted by β glucans. Killer mimotopes have shown in vitro an impressive microbicidal activity against Candida albicans. They were adopted as a model of PaKT- and PaKTscFvsusceptible microorganisms. Optimization through alanine scanning led to the generation of an engineered decapeptide (KP) of a CDR-L1 pertaining antibody fragment with an enhanced in vitro microbicidal activity. It had a potent therapeutic effect against experimental vaginal and systemic candidiasis in normal and immunodeficient mice caused by flucanozole susceptible and resistant yeast isolates. KP exerted a microbicidal activity in vitro against multidrug-resistant eukaryotic and prokaryotic pathogenic microorganisms, which was neutralized by interaction with laminarin (β 1,3-glucan). To our knowledge, KP represents the prototype of an engineered peptide fragment derived from a microbicidal recombinant antiidiotypic antibody. It is capable of exerting antimicrobial activity in vitro and a therapeutic effect in vivo presumably acting through interaction with the β glucan KTR component in the cell walls of pathogenic microorganisms.
Keywords: yeast killer toxin, synthetic peptides, killer mimotopes, antimicrobial therapy, antiidiotypic antibiotics, antiidiotypic therapy
Current Medicinal Chemistry
Title: Engineered Killer Mimotopes: New Synthetic Peptides for Antimicrobial Therapy
Volume: 11 Issue: 13
Author(s): W. Magliani, S. Conti, A. Salati, S. Arseni, L. Ravanetti, R. Frazzi and L. Polonelli
Affiliation:
Keywords: yeast killer toxin, synthetic peptides, killer mimotopes, antimicrobial therapy, antiidiotypic antibiotics, antiidiotypic therapy
Abstract: This review deals with a novel approach to produce synthetic antibiotic peptides (killer mimotopes), similar to those described for the conversion of epitopes into peptide mimotopes, allowing their use as surrogate vaccines. Synthetic peptides pertaining to the complementary determining regions (CDRs) of a recombinant antiidiotypic antibody (PaKTscFv), which mimic the wide spectrum of microbicidal activity of a killer toxin produced by the yeast Pichia anomala (PaKT), have proven to act as structural or functional mimotopes of PaKT. This activity appeared to be mediated by interaction with specific cell wall killer toxin receptors (KTRs), mainly constituted by β glucans. Killer mimotopes have shown in vitro an impressive microbicidal activity against Candida albicans. They were adopted as a model of PaKT- and PaKTscFvsusceptible microorganisms. Optimization through alanine scanning led to the generation of an engineered decapeptide (KP) of a CDR-L1 pertaining antibody fragment with an enhanced in vitro microbicidal activity. It had a potent therapeutic effect against experimental vaginal and systemic candidiasis in normal and immunodeficient mice caused by flucanozole susceptible and resistant yeast isolates. KP exerted a microbicidal activity in vitro against multidrug-resistant eukaryotic and prokaryotic pathogenic microorganisms, which was neutralized by interaction with laminarin (β 1,3-glucan). To our knowledge, KP represents the prototype of an engineered peptide fragment derived from a microbicidal recombinant antiidiotypic antibody. It is capable of exerting antimicrobial activity in vitro and a therapeutic effect in vivo presumably acting through interaction with the β glucan KTR component in the cell walls of pathogenic microorganisms.
Export Options
About this article
Cite this article as:
Magliani W., Conti S., Salati A., Arseni S., Ravanetti L., Frazzi R. and Polonelli L., Engineered Killer Mimotopes: New Synthetic Peptides for Antimicrobial Therapy, Current Medicinal Chemistry 2004; 11 (13) . https://dx.doi.org/10.2174/0929867043364964
DOI https://dx.doi.org/10.2174/0929867043364964 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
Call for Papers in Thematic Issues
Advances in Medicinal Chemistry: From Cancer to Chronic Diseases.
The broad spectrum of the issue will provide a comprehensive overview of emerging trends, novel therapeutic interventions, and translational insights that impact modern medicine. The primary focus will be diseases of global concern, including cancer, chronic pain, metabolic disorders, and autoimmune conditions, providing a broad overview of the advancements in ...read more
Approaches to the treatment of chronic inflammation
Chronic inflammation is a hallmark of numerous diseases, significantly impacting global health. Although chronic inflammation is a hot topic, not much has been written about approaches to its treatment. This thematic issue aims to showcase the latest advancements in chronic inflammation treatment and foster discussion on future directions in this ...read more
Cellular and Molecular Mechanisms of Non-Infectious Inflammatory Diseases: Focus on Clinical Implications
The Special Issue covers the results of the studies on cellular and molecular mechanisms of non-infectious inflammatory diseases, in particular, autoimmune rheumatic diseases, atherosclerotic cardiovascular disease and other age-related disorders such as type II diabetes, cancer, neurodegenerative disorders, etc. Review and research articles as well as methodology papers that summarize ...read more
Chalcogen-modified nucleic acid analogues
Chalcogen-modified nucleosides, nucleotides and oligonucleotides have been of great interest to scientific research for many years. The replacement of oxygen in the nucleobase, sugar or phosphate backbone by chalcogen atoms (sulfur, selenium, tellurium) gives these biomolecules unique properties resulting from their altered physical and chemical properties. The continuing interest in ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Impact and Therapeutic Potential of PPARs in Alzheimers Disease
Current Neuropharmacology Drug Loaded Erythrocytes: As Novel Drug Delivery System
Current Pharmaceutical Design Neurophysiological Mechanisms Related to Pain Management in Bone Tumors
Current Neuropharmacology The Role of the Endogenous Cannabinoid System in Peripheral Analgesia
Current Molecular Pharmacology Carcinogenesis and Diabetic Wound Healing: Evidences of Parallelism
Current Diabetes Reviews Signal Transduction through JAK-STAT and NF-κB Regulated Pim-1 Kinase: Novel Target for Anticancer Leads
Current Signal Transduction Therapy Non-Invasive Tests in Animal Models and Humans: A New Paradigm for Assessing Efficacy of Biologics Including Prebiotics and Probiotics
Current Pharmaceutical Design Targeting Glioblastoma: The Current State of Different Therapeutic Approaches
Current Neuropharmacology A Key Role for Connexin Hemichannels in Spreading Ischemic Brain Injury
Current Drug Targets Therapeutic Applications of Prostaglandins and Thromboxane A2 Inhibitors in Abdominal Aortic Aneurysms
Current Drug Targets Targeting Angiogenesis in Rheumatoid Arthritis
Current Rheumatology Reviews Cellular Therapeutics for Chronic Wound Healing: Future for Regenerative Medicine
Current Drug Targets The Inhibitory Role of M2000 (β-D-Mannuronic Acid) on Expression of Toll-like Receptor 2 and 4 in HT29 Cell Line
Recent Patents on Inflammation & Allergy Drug Discovery Role of microRNAs in Non-Alcoholic Steatohepatitis
Current Pharmaceutical Design The Effect of SEX/Gender on Cardiovascular Pharmacology
Current Pharmaceutical Design Nef and TNFα are Coplayers that Favor HIV-1 Replication in Monocytic Cells and Primary Macrophages
Current HIV Research Antioxidants as a Potential Preventive and Therapeutic Strategy for Cadmium
Current Drug Targets Mitochondrial genome sequencing in atherosclerosis: what's next?
Current Pharmaceutical Design Molecular Dynamics in Esophageal Adenocarcinoma: Who’s in Control?
Current Cancer Drug Targets A Review of the Characteristics, Properties and Methods for Quantification of Roxithromycin
Current Pharmaceutical Analysis